Endometriosis Treatment Market Size & Outlook, 2026-2034

Endometriosis Treatment Market Overview

The global endometriosis treatment market size is estimated at USD 2.01 billion in 2025 and is projected to reach USD 5.73 billion by 2034, growing at a CAGR of 12.37% during the forecast period. Sustained growth of the market is propelled by the increasing introduction of innovative therapeutics and diagnostic technologies aimed at improving early detection, personalised treatment, and long-term disease management outcomes for women affected by endometriosis.

Key Market Trends & Insights

• North America held a dominant share of the global market, accounting for 44.17%.
• The Asia Pacific region is growing at the fastest pace, with a CAGR of 14.48%.
• DrugType: The non-hormonal therapy segment is projected to register the fastest CAGR of 13.67% during the forecast period.
• Route of Administration: The oral route of administration dominated the market in 2025, with a revenue share of 57.89%.
• Distribution Channel: The hospital pharmacy segment accounted for the largest revenue share of 48.94% in 2025.
• The U.S. dominates the global market, valued at USD 720.00 million in 2024 and reaching USD 810.00 million in 2025.

Graph: U.S. Market Revenue Forecast (2022 – 2034)

Source: Straits Research

Market Size & Forecast

• 2025 Market Size: USD 2.01 billion
• 2034 Projected Market Size: USD 5.73 billion
• CAGR (2025 to 2034): 11.37%
• Dominating Region: North America
• Fastest Growing Region: Asia Pacific

The global endometriosis treatment market refers to the range of therapeutic products and interventions aimed at managing pain, inflammation, and fertility complications associated with endometriosis, a chronic condition in which endometrial-like tissue grows outside the uterus. The market is segmented by drug type, including hormonal therapies such as gonadotropin-releasing hormone (GnRH) agonists, oral contraceptives, progestins, and danazol, which regulate hormone levels to suppress lesion growth, and non-hormonal therapies like NSAIDs and analgesics that provide pain relief and control inflammation. Based on the route of administration, treatments are delivered through oral, injectable, nasal, and other forms such as implants and transdermal patches, ensuring diverse options for patient convenience and compliance. By distribution channel, the market includes hospital pharmacies, retail pharmacies, and others, including online and specialty pharmacies, ensuring broad accessibility across regions. Overall, the global endometriosis treatment market is expanding due to rising disease prevalence, growing awareness of women’s health, and continuous advancements in drug development focusing on non-hormonal, targeted, and patient-centric therapeutic approaches.

Latest Market Trends

Shift Toward Non-Hormonal and Targeted Therapeutic Approaches

The endometriosis treatment market is witnessing a shift toward the development of non-hormonal and targeted therapies that address the root causes of inflammation, angiogenesis, and pain associated with the disease. Traditional hormonal therapies, while efficient, often caused side effects such as bone density loss, mood changes, and infertility, prompting the need for safer alternatives. Pharmaceutical companies increasingly invested in novel drug classes such as selective progesterone receptor modulators (SPRMs), gonadotropin-releasing hormone (GnRH) antagonists with improved safety profiles, and small-molecule inhibitors targeting pathways like prostaglandin synthesis and immune modulation. For example, in 2025, several biotech firms initiated clinical trials for oral, non-hormonal compounds designed to relieve pain and prevent lesion growth without suppressing ovulation. This trend toward targeted and patient-friendly treatments is reshaping therapeutic strategies and expanding the potential for personalized endometriosis care.

Growing Adoption of Digital Health and AI-Driven Diagnostic Tools

The major trend in the endometriosis treatment market is the growing adoption of digital health platforms and artificial intelligence (AI)-driven diagnostic tools to enhance disease detection and management. Mobile health applications, wearable sensors, and telemedicine platforms are being integrated to track menstrual patterns, pain intensity, and hormonal fluctuations, enabling earlier identification of potential endometriosis symptoms. AI-powered imaging tools and machine learning algorithms are also improving diagnostic accuracy by analyzing MRI and ultrasound data to detect lesions non-invasively. In 2025, several startups launched AI-enabled women’s health platforms designed to provide predictive analytics and personalized treatment recommendations based on symptom data and medical history. This digital transformation enhanced patient engagement, facilitating early intervention, and supporting the global shift toward precision medicine in endometriosis management.

Endometriosis Treatment Market Driver

Rising Prevalence of Endometriosis and Increasing Awareness Driving Market Growth

A major driver for the endometriosis market is the rising global prevalence of the disease, coupled with growing awareness and improved recognition of women’s reproductive health disorders. According to recent epidemiological studies, endometriosis affects approximately 10% of women of reproductive age worldwide, creating a substantial patient pool requiring effective diagnosis and treatment. Increasing public health initiatives, advocacy campaigns, and educational programs led by organisations such as the World Endometriosis Society and national health agencies helped to reduce stigma, promote early consultation, and improved diagnosis rates. Additionally, expanding access to specialized gynaecological care and the introduction of new hormonal and non-hormonal therapies enhanced disease management outcomes. The growing involvement of pharmaceutical companies in research and clinical trials aimed at developing targeted and non-invasive treatment options further supported market expansion. This increasing prevalence, combined with heightened awareness and evolving therapeutic approaches, is driving the sustained growth of the global endometriosis market.

Market Restraint

Diagnostic Delays and Limited Accuracy of Current Detection Methods Restricting the Growth of the Endometriosis Market

A major restraint for the endometriosis market is the persistent challenge of delayed and inaccurate diagnosis due to the limitations of current detection methods. Most diagnostic procedures still rely on invasive laparoscopic surgery for definitive confirmation, which often results in an average diagnosis delay of 7 to 10 years after symptom onset. Non-specific symptoms such as pelvic pain, fatigue, and infertility frequently overlap with other gynaecological or gastrointestinal disorders, leading to misdiagnosis or underdiagnosis. Furthermore, the absence of reliable, standardized biomarkers and limited accessibility to advanced imaging technologies in low- and middle-income regions further hinder early identification and treatment. These diagnostic inefficiencies not only delay clinical intervention but also contributed to disease progression, reduced quality of life, and higher healthcare costs. The lack of accurate, affordable, and non-invasive diagnostic solutions continues to be a significant barrier to the growth and effective management of the global endometriosis market.

Market Opportunity

Advancements in Non-Invasive Diagnostic Technologies Offering Significant Growth Opportunities for the Endometriosis Market

A major opportunity for the endometriosis market arises from the rapid development and integration of non-invasive diagnostic technologies aimed at improving early detection and disease management. Current diagnostic methods often rely on laparoscopic surgery, leading to delayed diagnosis and treatment. However, innovations in molecular diagnostics, liquid biopsy, and imaging-based approaches, such as MRI radiomics and AI-driven ultrasound analysis, are transforming disease identification by offering faster, safer, and more accurate assessments. Emerging biomarkers from blood, urine, and menstrual effluent are also enabling the development of point-of-care testing solutions that can identify endometriosis at earlier stages. Furthermore, growing collaborations between biotechnology firms and academic institutions are accelerating research on predictive models and companion diagnostics to guide personalized treatment strategies. As non-invasive tools gain regulatory validation and clinical adoption, they are expected to create substantial opportunities for companies developing advanced diagnostic platforms in the global endometriosis market.

Regional Analysis

North America region dominated the market in 2025, with a revenue share 44.17%. The market growth in the region is primarily driven by the increasing adoption of advanced hormonal therapies and non-invasive diagnostics, coupled with rising awareness of early disease management among women of reproductive age.

The U.S. market growth is driven by intensive R&D investments in novel drug formulations and precision hormone modulation therapies. The country hosts major pharmaceutical companies such as AbbVie, Pfizer, and Myovant Sciences that are expanding their clinical pipelines for long-term disease management solutions. In addition, the growing adoption of digital health tools for symptom tracking and fertility management is enhancing patient engagement and early diagnosis. Federal funding through the National Institutes of Health (NIH) for endometriosis research programs has further reinforced the U.S. as a global leader in therapeutic advancement and patient-centered care.

Asia Pacific Endometriosis Treatment Insights

Asia Pacific region is anticipated to register the fastest CAGR of 14.48% during the forecast period. The driving factor for this growth is the rapid expansion of women’s healthcare infrastructure and government-backed reproductive health programs. Increasing prevalence of endometriosis among younger populations, combined with improved diagnostic awareness and access to gynecologic care, is boosting market demand. Regional biotech startups are focusing on developing cost effective hormonal drugs and localized treatment regimens to cater to population needs.

India Market: India’s market growth is propelled by the rising focus on affordable women’s health therapeutics and indigenous drug manufacturing initiatives. Government led programs under the “Ayushman Bharat” and “Make in India” missions are encouraging domestic production of hormonal therapy formulations. Academic and industry partnerships are advancing clinical studies on herbal and nonhormonal agents for pain relief, while patient advocacy campaigns are promoting early diagnosis and public awareness. These initiatives collectively position India as a growing hub for cost efficient endometriosis care and research.

By Region Market Share (in percent share %), 2025

Source: Straits Research

Europe Endometriosis Treatment Insights

Europe’s market growth is fueled by regulatory harmonization and the high adoption of evidence based hormonal and surgical interventions. The European Medicines Agency (EMA) and national health authorities have implemented standardized guidelines for endometriosis diagnosis, ensuring consistent clinical outcomes across healthcare systems. Pharmaceutical companies are increasingly investing in sustainable women’s health portfolios and cross border collaborations to introduce innovative nonsurgical therapies and patient assist programs.

Germany’s market expansion is supported by strong integration between clinical research institutions and pharmaceutical manufacturers. Federally funded consortia are advancing studies on the molecular mechanisms of endometrial tissue growth and personalized treatment protocols. Local biotech firms are developing novel drug delivery platforms and minimally invasive surgical devices for lesion removal. This combination of academic excellence and technological innovation secures Germany’s position as a European leader in endometriosis treatment development.

Latin America Endometriosis Treatment Insights

The Latin American market is growing steadily due to increasing healthcare investments in women’s reproductive medicine and the establishment of specialized gynecology clinics. Rising awareness campaigns supported by public health ministries and international organizations are helping to reduce diagnostic delays, which remain high in the region. Regional research initiatives are focusing on epidemiological studies and culturally adapted therapeutic models to improve treatment adherence and accessibility.

Brazil’s market growth is driven by public and private partnerships aimed at enhancing women’s reproductive health services and clinical outreach programs. The Ministry of Health is supporting nationwide screening campaigns and telemedicine platforms for early endometriosis diagnosis, especially in underserved regions. Additionally, collaborations with local universities are fostering clinical trials on generic hormonal therapies and pain relief alternatives, strengthening Brazil’s role as a regional hub for affordable and inclusive women’s healthcare.

Middle East and Africa Endometriosis Treatment Insights

The Middle East and Africa (MEA) region is experiencing notable growth due to increasing cross border healthcare collaborations and expansion of fertility and women’s health centers. Governments are investing in awareness initiatives, digital diagnosis tools, and minimally invasive treatment facilities, reflecting a broader commitment to women’s reproductive wellbeing. Partnerships with international pharmaceutical companies are enhancing access to advanced hormonal therapies and clinical education programs.

The UAE market growth is supported by the expansion of multidisciplinary reproductive health centers and personalized medicine programs. Government initiatives under the “National Strategy for Wellbeing 2031” are promoting endometriosis awareness and facilitating access to specialist gynaecological care. Collaborations between global pharmaceutical firms and UAE based hospitals are driving the availability of advanced hormonal therapies and fertility management treatments. These developments reinforce the UAE’s position as a regional leader in women’s healthcare and reproductive innovation.

Drug Type Insights

The hormonal therapy segment dominated the global endometriosis treatment market in 2025, accounting for the largest revenue share due to its efficiency in controlling the hormonal imbalance that drives endometrial tissue growth. 

The non hormonal therapy segment is projected to register the fastest CAGR of 13.67% during the forecast period, driven by the rising demand for alternative pain management approaches and supportive treatments. The increasing use of NSAIDs and non-opioid analgesics for symptomatic relief among patients intolerant to hormonal medications is fueling segment growth. Continued research into non-hormonal molecules targeting inflammation and neurogenic pain pathways is expected to broaden therapeutic options in the coming years.

Route of Administration Insights

The oral route of administration dominated the market in 2025, with a revenue share of  57.89%, owing to its convenience, patient compliance, and wide availability of oral hormonal formulations, including elagolix (Orilissa) and combined oral contraceptives. The growing adoption of oral GnRH antagonists as first-line therapy for moderate to severe pain has reinforced this segment’s leadership position.

The injectables segment is anticipated to record the fastest CAGR of 13.83% during the forecast period, attributed to the expanding use of long-acting GnRH agonist depot injections and progestin-based injectables for sustained symptom suppression. Advances in parenteral drug delivery systems offering controlled release and reduced dosing frequency are improving patient adherence and clinical outcomes.

By Route of Administration Market Share (in percent share %), 2025

Source: Straits Research

Distribution Channel Insights

The hospital pharmacy segment accounted for the largest revenue share of 48.94% in 2025, driven by the growing number of women seeking specialized gynaecological and fertility care in hospital settings. The presence of multidisciplinary care centers and access to advanced hormonal therapies support strong hospital-based dispensing.

The retail pharmacy segment is expected to witness the fastest CAGR of 13.04% during the forecast period, primarily due to increasing over-the-counter (OTC) availability of analgesics, oral contraceptives, and nonprescription pain relief products for endometriosis symptom management. Rising digital pharmacy adoption and online prescription services are also contributing to this growth.

Competitive Landscape

The global endometriosis treatment market is moderately consolidated, characterized by the presence of established pharmaceutical giants and emerging biopharmaceutical firms focused on innovative hormonal, non-hormonal, and surgical therapy solutions.

AbbVie Inc. emerging market player

AbbVie, a U.S.based biopharmaceutical company, emerged as a dominant player in endometriosis treatment with its FDA approved oral GnRH antagonist, Orilissa (elagolix), developed to manage moderate to severe pain associated with endometriosis. The company continued to expand its women’s health portfolio through strategic collaborations and long term research on hormonal regulation therapies.

List of key players in Endometriosis Treatment Market

1. AbbVie Inc.
2. Bayer AG
3. Pfizer Inc.
4. Myovant Sciences Ltd.
5. TerSera Therapeutics LLC
6. ASKA Pharmaceutical Co., Ltd
7. Takeda Pharmaceutical Company Limited
8. Ferring
9. Merck & Co., Inc.
10. Gedeon Richter Plc
11. Sanofi
12. Teva Pharmaceutical Industries Ltd.
13. Astellas Pharma Inc.
14. Kissei Pharmaceutical Co., Ltd.
15. ObsEva SA
16. Johnson & Johnson
17. Eli Lilly and Company
18. Lupin Limited
19. Sun Pharmaceutical Industries Limited
20. Beijing Biote Pharmaceutical Co., Ltd
21. Others

To get more findings about this report Download Market Share

Strategic Initiatives

• March 2025: EDAP received CE Mark certification for its Focal One Robotics HIFU System for the treatment of deep-infiltrating endometriosis, with the designation granted by its notified body, GMED.
• March 2025: Heranova Lifesciences Inc. announced the completion of laboratory development test (ldt) validation for its non-invasive diagnostic test, HerResolve, developed to transform the management of endometriosis. The test is planned for launch at selected clinical centers across the U.S..
• October 2024: Lisata Therapeutics, Inc. entered into a sponsored research agreement with the University of Cincinnati to evaluate its cyclic peptide candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor), in a preclinical animal model for the treatment of endometriosis.